BCA
ACAD icon

Berman Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Berman Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$15K Buy
944
+557
+144% +$10.7K ﹤0.01% 1062
2021
Q2 		$9K Sell
387
-419
-52% -$9.46K ﹤0.01% 1149
2021
Q1 		$20K Buy
+806
New +$35.5K ﹤0.01% 784

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Berman Capital Advisors's ACAD Position: Q3 2021 in Review

Berman Capital Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 144% in Q3 2021, buying an estimated $10.7K and bringing the position to 944 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1062.

Berman Capital Advisors first reported a position in ACAD in Q1 2021 and has held it in 3 quarters since. The position peaked at $20K in Q1 2021. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

  • Berman Capital Advisors held 944 shares of Acadia Pharmaceuticals worth $15K as of Q3 2021.
  • Berman Capital Advisors bought 557 Acadia Pharmaceuticals shares in Q3 2021, an estimated $10.7K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1062 holding.
  • Berman Capital Advisors first reported a position in Acadia Pharmaceuticals in Q1 2021 and has held it in 3 quarters since.
  • Berman Capital Advisors's Acadia Pharmaceuticals position peaked at $20K in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.